Tokyo, Nov. 6 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059654) titled 'Hemostatic Single 8 Gy radiotherapy for Tumor bleeding Palliation' on Nov. 6.
Study Type:
Observational
Primary Sponsor:
Institute - National Cancer Center
Condition:
Condition - All cancers with tumor-related bleeding
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate hemostatic efficacy following a single 8 Gy palliative radiotherapy
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1) Patients scheduled to receive radiotherapy with a single 8 Gy fraction for tumor-related bleeding
2) Patients aged 20 years or older at the time of obtaining consent
3) Patients who have provided oral informed consent
Key exclusion criteria - 1) Patients for whom follow-up is expected to be difficult (e.g., those living far from the hospital or with a performance status of 4 or higher)
Target Size - 100
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 01 Month 14 Day
Date of IRB - 2025 Year 01 Month 24 Day
Anticipated trial start date - 2025 Year 02 Month 17 Day
Last follow-up date - 2028 Year 02 Month 29 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068239
Disclaimer: Curated by HT Syndication.
